“Effect of Hormone Resistance Type on First-Line Treatment Selection in ER+/HER2-Negative Metastatic Breast Cancer”, Вопр. онкол., vol. 72, no. 3, p. OF-2675, Jul. 2026, doi: 10.37469/0507-3758-2026-72-3-OF-2675.